Eric D. Carruth

Eric D. Carruth

Auto-generated profile, based on publicly available information

Eric D. Carruth

Department of Genomic Health, Geisinger, Danville, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2025 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
DLDavid S. M. Lee
David S. M. Lee
KCKathleen M. Cardone
Kathleen M. Cardone
DZDavid Y. Zhang
David Y. Zhang
NTNoah L. Tsao
Noah L. Tsao
SASarah Abramowitz
Sarah Abramowitz
ODOzan Dilitikas
Ozan Dilitikas

7 October 2025 in Circulation
Verified
Journal Article
Closed access
AGAlessio Gasperetti
Alessio Gasperetti
SMSteven A. Muller
Steven A. Muller
Giovanni PerettoGiovanni Peretto
Giovanni Peretto
BABabken Asatryan
Babken Asatryan
APAlexandros Protonotarios
Alexandros Protonotarios
NGNisha A. Gilotra
Nisha A. Gilotra
BACKGROUND: Inflammatory, myocarditis-like episodes precede and are associated with higher risk of sustained ventricular arrhythmias and heart failure in patients with pathogenic or likely pathogenic desmoplakin (DSP) variants. Whether the recurrence and treatment of myocarditis-like episodes influence the outcomes in this population is unknown. This study aimed to assess the prognostic impact of the recurrence and treatment of myocarditis-like episodes in patients with pathogenic or likely pathogenic DSP variants. METHODS: The study was designed as an observational cohort study using all patients with pathogenic or likely pathogenic DSP variants in the DSP -ERADOS Network ( Desmopakin Specific Effort for a Rare Disease Outcome Study) enrolled at 31 institutions up until April 30, 2024. Survival from ventricular arrhythmia and heart failure end points and recurrent myocarditis-like episodes was evaluated for both first and recurrent documented myocarditis-like episodes and the impact of immunosuppressive treatment on outcomes assessed. RESULTS: A total of 1014 patients with pathogenic or likely pathogenic DSP variants (62.4% female; mean age, 40.4±17.4 years; 47.1% probands) were included. Among them, 177 individuals (17.5%) experienced ≥1 documented myocarditis-like episode, with 63 of them (35.6%) receiving immunosuppressive treatment. Immunosuppressive treatment of the first documented myocarditis-like episode was associated with reduced risk of ventricular arrhythmia and heart failure outcomes (hazard ratio, 0.18 [95% CI, 0.07–0.45]; P <0.001; and hazard ratio, 0.09 [95% CI, 0.02–0.39; P =0.001, respectively) over a median follow-up of 6.4 years (95% CI, 4.0–10.5). This risk was comparable to that of patients with no history of myocarditis-like episode but did not correlate with a reduction in recurrent episodes after completion of initial immunosuppression (hazard ratio, 0.85 [95% CI, 0.47–1.54]; P =0.599). In contrast, nonsteroidal anti-inflammatory drugs or colchicine treatment did not influence outcomes. CONCLUSIONS: Immunosuppressive treatment of myocarditis-like episodes in DSP patients was associated with improved combined ventricular arrhythmia or heart failure outcomes, supporting future prospective evaluation in DSP cohorts.

1 August 2022 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
PDF file
ECEric D. Carruth
Eric D. Carruth
MQMaria Qureshi
Maria Qureshi
AAAmro Alsaid
Amro Alsaid
MKMelissa A. Kelly
Melissa A. Kelly
HCHugh Calkins
Hugh Calkins
CHChristopher M. Haggerty
Christopher M. Haggerty
Background: The FLNC gene has recently garnered attention as a likely cause of arrhythmogenic cardiomyopathy, which is considered an actionable genetic condition. However, the association with disease in an unselected clinical population is unknown. We hypothesized that individuals with loss-of-function variants in FLNC ( FLNC LOF ) would have increased odds for arrhythmogenic cardiomyopathy-associated phenotypes versus variant-negative controls in the Geisinger MyCode cohort. Methods: We identified rare, putative FLNC LOF among 171 948 individuals with exome sequencing linked to health records. Associations with arrhythmogenic cardiomyopathy phenotypes from available diagnoses and cardiac evaluations were investigated. Results: Sixty individuals (0.03%; median age 58 years [47–70 interquartile range], 43% male) harbored 27 unique FLNC LOF . These individuals had significantly increased odds ratios for dilated cardiomyopathy (odds ratio, 4.9 [95% CI, 2.6–7.6]; P <0.001), supraventricular tachycardia (odds ratio, 3.2 [95% CI, 1.1–5.6]; P =0.048), and left-dominant arrhythmogenic cardiomyopathy (odds ratio, 4.2 [95% CI, 1.4–7.9]; P =0.03). Echocardiography revealed reduced left ventricular ejection fraction (52±13% versus 57±9%; P =0.001) associated with FLNC LOF . Overall, at least 9% of FLNC LOF patients demonstrated evidence of penetrant disease. Conclusions: FLNC LOF variants are associated with increased odds of ventricular arrhythmia and dysfunction in an unselected clinical population. These findings support genomic screening of FLNC for actionable secondary findings.

3 March 2020 in Magnetic Resonance in Medicine
Verified
Journal Article
Open access
PDF file
ITIrvin Teh
Irvin Teh
DMDarryl McClymont
Darryl McClymont
ECEric Carruth
Eric Carruth
JOJeffrey Omens
Jeffrey Omens
Andrew McCullochAndrew McCulloch
Andrew McCulloch
JSJürgen E. Schneider
Jürgen E. Schneider
Purpose: Structure‐guided total variation is a recently introduced prior that allows reconstruction of images using knowledge of the location and orientation of edges in a reference image. In this work, we demonstrate the advantages of a variant of structure‐guided total variation known as directional total variation (DTV), over traditional total variation (TV), in the context of compressed‐sensing reconstruction and super‐resolution.Methods: We compared TV and DTV in retrospectively undersampled ex vivo diffusion tensor imaging and diffusion spectrum imaging data from healthy, sham, and hypertrophic rat hearts.Results: In compressed sensing at an undersampling factor of 8, the RMS error of mean diffusivity and fractional anisotropy relative to the fully sampled ground truth were 44% and 20% lower in DTV compared with TV. In super‐resolution, these values were 29% and 14%, respectively. Similarly, we observed improvements in helix angle, transverse angle, sheetlet elevation, and sheetlet azimuth. The RMS error of the diffusion kurtosis in the undersampled data relative to the ground truth was uniformly lower (22% on average) with DTV compared to TV.Conclusion: Acquiring one fully sampled non‐diffusion‐weighted image and 10 diffusion‐weighted images at 8× undersampling would result in an 80% net reduction in data needed. We demonstrate efficacy of the DTV algorithm over TV in reducing data sampling requirements, which can be translated into higher apparent resolution and potentially shorter scan times. This method would be equally applicable in diffusion MRI applications outside the heart.

1 April 2021 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
PDF file
ECEric D. Carruth
Eric D. Carruth
DBDominik Beer
Dominik Beer
AAAmro Alsaid
Amro Alsaid
MSMarci L.B. Schwartz
Marci L.B. Schwartz
MMMegan McMinn
Megan McMinn
CHChristopher M. Haggerty
Christopher M. Haggerty
Background: Genomic screening holds great promise for presymptomatic identification of hidden disease, and prevention of dramatic events, including sudden cardiac death associated with arrhythmogenic cardiomyopathy (ACM). Herein, we present findings from clinical follow-up of carriers of ACM-associated pathogenic/likely pathogenic desmosome variants ascertained through genomic screening. Methods: Of 64 548 eligible participants in Geisinger MyCode Genomic Screening and Counseling program (2015–present), 92 individuals (0.14%) identified with pathogenic/likely pathogenic desmosome variants by clinical laboratory testing were referred for evaluation. We reviewed preresult medical history, patient-reported family history, and diagnostic testing results to assess both arrhythmogenic right ventricular cardiomyopathy and left-dominant ACM. Results: One carrier had a prior diagnosis of dilated cardiomyopathy with arrhythmia; no other related diagnoses or diagnostic family history criteria were reported. Fifty-nine carriers (64%) had diagnostic testing in follow-up. Excluding the variant, 21/59 carriers satisfied at least one arrhythmogenic right ventricular cardiomyopathy task force criterion, 11 (52%) of whom harbored DSP variants, but only 5 exhibited multiple criteria. Six (10%) carriers demonstrated evidence of left-dominant ACM, including high rates of atypical late gadolinium enhancement by magnetic resonance imaging and nonsustained ventricular tachycardia. Two individuals received new cardiomyopathy diagnoses and received defibrillators for primary prevention. Conclusions: Genomic screening for pathogenic/likely pathogenic variants in desmosome genes can uncover both left- and right-dominant ACM. Findings of overt cardiomyopathy were limited but were most common in DSP -variant carriers and notably absent in PKP2 -variant carriers. Consideration of the pathogenic/likely pathogenic variant as a major criterion for diagnosis is inappropriate in the setting of genomic screening.

9 July 2021 in Cardiovascular Engineering and Technology
Verified
Journal Article
Closed access
PDF file
ECEric D. Carruth
Eric D. Carruth
SFSamuel W. Fielden
Samuel W. Fielden
CNChristopher D. Nevius
Christopher D. Nevius
BFBrandon K. Fornwalt
Brandon K. Fornwalt
CHChristopher M. Haggerty
Christopher M. Haggerty